• Lei Liu, Xiang Wang, Wen-Bin Wu, and Miao Zhang.
• Institute of Digestive Disease, China Three Gorges University, Department of Gastroenterology of Yichang Central People's Hospital, Yichang, China.
• Medicine (Baltimore). 2020 Oct 9; 99 (41): e22707.

RationaleAnlotinib has been proved to be effective in advanced refractory non-small cell lung cancer.Patient ConcernsA 47-year-old female non-smoker was admitted due to persistent chest tightness for a month.DiagnosesEpidermal growth factor receptor (EGFR) wild-type advanced primary lung adenocarcinoma without brain or bone metastasis.InterventionsThe patient failed 2 lines of pemetrexed/docetaxel plus carboplatin and third-line erlotinib. Fourth-line anlotinib was administered thereafter.OutcomesThe pulmonary lesions showed partial remission 5 months after anlotinib monotherapy. The patient demonstrated a progression-free survival of more than 7 months and an overall survival of >12 months. The adverse events including hypertension and fatigue were well-tolerated.LessonsSalvage anlotinib might be a reasonable choice in EGFR wild-type lung adenocarcinoma after failure of chemotherapy. Further well-designed trials are warranted to verify this occasional finding.

25 keywords...

hide…